Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Further Placing

28 Mar 2008 09:00

ReGen Therapeutics PLC28 March 2008 28 March 2008 ReGen Therapeutics Plc Further Placing ReGen Therapeutics Plc ("ReGen" or the "Company", AIM: RGT) is pleased toannounce that further to the placing of 629,685 new ordinary shares which wasannounced on 26 March 2008 ("the Placing"), and in order to satisfy marketdemand, a further placing ("the Further Placing") has been arranged. The Company has today placed through Alexander David Securities Limited, 130,000new ordinary shares of 10p each at 32.5p per share, (the same terms as thePlacing) and as a result has raised £42,250 before expenses of the issue. In addition, ReGen has today issued 138,889 new ordinary shares to Duke HoldingsCorporation Limited ("Duke") as payment of the drawdown fees under the equitycredit facility agreement announced on 26 March 2008. The total of 268,889 new ordinary shares, which will represent 2.41% per cent ofthe enlarged issued share capital of the Company, will rank pari passu in allrespects with the existing ordinary shares in the Company. Application will be made to the London Stock Exchange for the new ordinaryshares to be admitted to trading on AIM and dealings in the new ordinary sharesare expected to commence on 2 April 2008. For further information, please contact: Percy LomaxReGen Therapeutics PlcTel: 020 7153 4920 Roland Cornish/Felicity GeidtBeaumont Cornish LimitedTel No 020 7628 3396 David Scott/Nick BealerAlexander David Securities LimitedTel: 020 7448 9800 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th May 20197:00 amRNS9th Annual LD Micro Invitational
7th May 20197:00 amRNSNotice of AGM
2nd May 20197:00 amRNSDirector/PDMR Shareholding
1st May 20197:00 amRNSUpdate on IND Application
25th Apr 20195:00 pmRNSDirector/PDMR Shareholding
24th Apr 201912:55 pmRNSReissue: Interim Clinical Data
24th Apr 20197:00 amRNSInterim Clinical Data
15th Apr 20195:45 pmRNSHolding(s) in Company
15th Apr 20195:45 pmRNSHolding(s) in Company
15th Apr 20195:45 pmRNSHolding(s) in Company
4th Apr 20197:00 amRNSFinal Results
20th Mar 20197:00 amRNSIND Application Submitted for NASH Oral Treatment
7th Feb 20197:00 amRNSDirectorate Change
11th Dec 20187:00 amRNSExercise of Warrants & Issue of Equity
3rd Dec 20187:00 amRNSMilciclib HCC Phase IIa Trial Enrollment Completed
28th Nov 20187:00 amRNSForalumab: Phase 1 Trial with Nasal Administration
27th Nov 20187:00 amRNSHolding(s) in Company
26th Nov 20187:00 amRNSStatement re: ADSs
23rd Nov 20185:00 pmRNSClosing of Offering and Total Voting Rights
20th Nov 20187:30 amRNSDiscounted exercise prices of outstanding warrants
20th Nov 20187:00 amRNSOffer Pricing, Nasdaq Listing & Loan Conversion
18th Oct 20187:15 amRNSAmended Registration Statement filed with the SEC
16th Oct 20187:00 amRNSMilciclib synergistic activity presented at AASLD
25th Sep 20187:00 amRNSTiziana announces Offering & Application to Nasdaq
24th Sep 20187:03 amRNSInterim Results for Six Months Ended 30 June 2018
24th Sep 20187:00 amRNSU.S. FDA Approval IND Nasal Foralumab Phase 1
13th Sep 20181:05 pmRNSPDMR Dealing
12th Sep 20187:00 amRNSPDMR dealings
11th Sep 20187:00 amRNSPDMR Dealing
24th Aug 20187:00 amRNSPDMR Dealing
21st Aug 20187:00 amRNSPDMR dealings
20th Aug 20187:00 amRNSPDMR Dealing
17th Aug 20187:00 amRNSPDMR Dealing
16th Aug 20189:00 amRNSFiling of Investigational New Drug application
27th Jul 20187:00 amRNSUS Registration Statement for Proposed Offering
25th Jun 201810:49 amRNSResult of AGM
7th Jun 20187:01 amRNSAppointment of Broker
7th Jun 20187:00 amRNSFinal Results
1st Jun 20187:00 amRNSNotice of AGM
23rd May 20184:40 pmRNSSecond Price Monitoring Extn
23rd May 20184:35 pmRNSPrice Monitoring Extension
16th May 20187:00 amRNSMilciclib Phase 2a Trial - Tolerability Update
1st May 20183:00 pmRNSGrant of Options - Director Dealing
27th Apr 20187:00 amRNSIssue of Equity
19th Apr 20187:00 amRNSSubscription
16th Apr 20187:25 amRNSLicense Agreement
9th Apr 20188:25 amRNSPresentation at ASCO 3 June 2018
5th Apr 20187:00 amRNSAppointment of Broker
4th Apr 20187:00 amRNSAppointment of Director
5th Mar 20187:00 amRNSPlacing to raise £600,000 and issue of equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.